Skip to main content
Premium Trial:

Request an Annual Quote

Biocept Prices Subscription Rights to Purchase $25M of Securities

NEW YORK (GenomeWeb) – Biocept on Tuesday provided details regarding its previously announced plans to distribute subscription rights to certain shareholders of its common stock and warrants to purchase 25,000 securities units for a total of $25 million.

Biocept originally announced the distribution of the subscription rights in May. The subscription rights are being distributed to holders of common stock and warrants that Biocept issued Feb. 13, 2015; May 4, 2016; Oct. 19 2016; March 31, 2017; Aug. 9, 2017; and Jan. 30, 2018.

In an amended preliminary prospectus filed on Tuesday with the US Securities and Exchange Commission, the company said that each subscription right entitles those investors to purchase one unit at a subscription price of $1,000 per unit. Each unit comprises one share of Series A convertible preferred stock and 220 warrants. The preferred stock has a value of $1,000 per share. Each warrant will be exercisable for one share of the company's common stock at an exercise price of $4.53 per share. Warrants can be exercised for five years from the date of issuance.

The Maxim Group and Dawson James Securities are the co-dealer managers in the offering.

Net proceeds from the exercise of subscription rights and warrants are anticipated to be $22.6 million, excluding any proceeds from the exercise of warrants. Biocept said that it intends to use the proceeds for general corporate purposes, including R&D expenses, capital spending, working capital and general and administrative expenses, and potential acquisitions of or investments in businesses, products, or technologies.

Biocept raised $13.3 million in January in a public offering of its common stock.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.